BOSTON–(BUSINESS WIRE)–20/20 Onsite, a Boston-based eye care company, proudly announces its recent achievement at the Massachusetts Innovation Network 2023 Eddies Awards. The company has been honored with the esteemed Eddies Award in the Healthy Living category for its innovative approach to addressing challenges in vision care accessibility and revolutionizing the landscape of clinical trials.
The Eddies Awards, known for celebrating excellence in diverse industries, have recognized 20/20 Onsite for its outstanding contribution to promoting healthier living through its unique blend of accessible eye care and groundbreaking advancements in clinical trial delivery.
Since 2014, 20/20 Onsite has provided care to over 75,000 patients, 450+ corporate clients, and 15 clinical trials. Their solution brings high quality care directly to patients, which unleashes demand, expands access to care, and delivers high value services that would not take place otherwise.
Accessing high quality eye care is a growing challenge. While 75% of the population experiences vision loss, only 33% get their annual eye exam. 20/20 Onsite breaks down these barriers to routine care by bringing vision care directly to patients at their workplaces, residences and schools.
Clinical trials face an even more severe challenge. Trials frequently bear costly delays associated with fulfilling the ocular examination component present in 20% of all protocols. These challenges include the patient burden of travel and time investment, the difficulty outsourcing, the staffing shortage for ophthalmologists, and the expense of equipment. 20/20 Onsite has been a catalyst for change in this industry as they have implemented innovative solutions to remove these barriers in trials across therapeutic areas and in phases 1-4. Their highly-skilled team brings high quality assessments to patients at a variety of locations including study sites or directly at their homes.
“We are thrilled to recognize 20/20 Onsite with the Eddies Award in the Health Living category,” says Sophia Kambanis, Executive Director, Massachusetts Innovation Network. “Their pioneering efforts in bringing eye care directly to communities and their innovative approach to addressing barriers in clinical trial participation truly set them apart. The 20/20 Onsite team is well-deserved of this prestigious award and we look forward to supporting their continued dedication to advancing healthcare accessibility.”
The Eddies Competition is an 8-month long innovation-fueling program that started back in March with nearly 100 applications from New England startups. 18 teams advanced to the final phase of the competition which included pitches and exhibits of the technologies. Throughout the program, the finalists received individualized mentorship, specifically designed supplemental entrepreneurial development modules to address their needs, and hands-on support to advance them towards their commercialization and scaling journey. The program culminated on November 8th for a night of celebration, during which eight companies were honored with The Eddie Award. Prior Eddies Award winners include Hubspot, Staples, Keurig, Genzyme, iRobot, MathWorks, Ben & Jerry’s, and many more outstanding companies.
“This recognition and achievement inspires us to continue pushing boundaries in healthcare delivery. We are so grateful to the Eddies leadership team, the mentors, and the judges. We are proud to be at the forefront of innovation in healthcare, along with many of the companies in this year’s Eddies finalist cohort. The entire team at 20/20 Onsite is looking forward to bringing primary vision care and clinical trials to many more patients in the future, and advancing our mission to make eye care accessible to all.” -20/20 Onsite CEO Sonali Bloom
About 20/20 Onsite:
20/20 Onsite is a health care services company that is transforming the delivery of vision care by radically improving access for patients through state-of-the-art Mobile Vision Clinics. Since 2014, their integrated mobile service delivery platform has taken high value eye care services directly to patients at work, at school, and more recently, at convenient neighborhood locations in the Northeast. In the midst of the pandemic, 20/20 Onsite began bringing ophthalmic assessments to patients in clinical trials or post-marketing safety surveillance programs across the country, increasing access to clinical research. They are disrupting the way eye care is delivered, and are enabling and accelerating fundamental trends toward the consumerization of care and the decentralization of clinical trials.
20/20 Onsite serves over 450 corporate clients, educational institutions, and other organizations with comprehensive eye care for their employees, and their patient base of 75,000+ consistently reports NPS over 93.
Sonali Bloom, CEO of 20/20 Onsite